DURECT (DRRX) Q4 2024 earnings summary

Executive summary

• Focused on developing larsucosterol for alcohol-associated hepatitis, a disease with high mortality and no approved therapies; achieved key milestones including FDA breakthrough therapy designation and NEJM Evidence publication.

• Sole corporate focus is securing funding to initiate a phase III trial for larsucosterol, with Phase 2b AHFIRM trial results informing Phase 3 design.

• Completed sale of ALZET product line for $17.5 million, using proceeds to fully repay term loan and strengthen balance sheet.

Financial highlights

• 2024 revenues were $2 million, down from $2.6 million in 2023; Q4 2024 revenues were $0.5 million, down from $0.9 million in Q4 2023.

• R&D expenses dropped to $10.4 million in 2024 from $29.4 million in 2023; Q4 R&D was $1.9 million, down from $5.6 million.

• SG&A expenses decreased to $10 million in 2024 from $12.7 million in 2023; Q4 SG&A was $2 million, down from $2.2 million.

• Net income for Q4 2024 was $7.8 million, compared to a $1.4 million net loss in Q4 2023; FY 2024 net loss was $7.9 million, compared to $27.6 million in FY 2023.

• Cash and investments at year-end 2024 were $12 million, compared to $29.8 million at the end of 2023.

Outlook and guidance

• Cash on hand is expected to fund operations through Q3 2025.

• Phase III trial for larsucosterol is ready to initiate upon securing approximately $20 million in funding; topline data expected within two years after trial start.

• Actively exploring strategic partnerships, business development, and capital market opportunities to fund clinical development.